ADVA-OPTICAL-NETWORKING
25.6.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Central Bank of Austria is deploying its FSP 3000 technology in a new, highly reliable, ultra-secure data center interconnect (DCI) network. With capacity for up to 32Gbit/s Fibre Channel and 100Gbit/s Ethernet services, the infrastructure provides robust, high-speed disaster recovery and business continuity capabilities that are essential for mission-critical operations. It’s protected by ADVA’s ConnectGuard™ Optical encryption and the real-time assurance of the ADVA ALM fiber monitoring solution. ADVA’s open modular FSP 3000 platform ensures that the bank’s redundant point-to-point system is easily scalable and highly efficient with space and power consumption. The network was installed by ADVA’s partners Componet and dacoso, who are also providing ongoing support with maintenance and SLA management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005079/en/
“Our customers demand world-class services with unbeatable security and availability. That’s why we’re committed to harnessing the most innovative technology on the market. Built on the ADVA FSP 3000 and secured by ConnectGuard™ Optical encryption, our new DCI network supports the fastest, most advanced SAN connectivity available, ensuring mission-critical data is always accessible and fully protected,” said Daniela Karanitsch, head of IT operations, Central Bank of Austria. “This flexible, high-capacity solution empowers us to tackle huge increases in data demand while also making significant savings on rack space and power consumption. What’s more, its efficiency and sustainability is further enhanced by ADVA’s ALM fiber monitoring technology, which provides round-the-clock visibility and assurance of the entire network.”
The Central Bank of Austria’s new network can transport up to 200Gbit/s on a single wavelength. It supports a wide range of services on one platform, including 1, 10, 25, 40 and 100Gbit/s Ethernet as well as 8, 16 and 32Gbit/s Fibre Channel. That flexibility enables the bank to maximize efficiency as it responds to changing customer requirements. Austria’s most sensitive financial data is now being safeguarded by encryption at the lowest network layer, guaranteeing resilient protection with none of the latency and performance problems that come with other security methods. ADVA’s FSP 3000 ConnectGuard™ Optical was the first encryption solution on the market to support Fibre Channel speeds up to 32Gbit/s. It’s still the only one capable of such speeds to achieve BSI-approved status, enabling its use for EU and NATO restricted data.
“Our FSP 3000 platform gives the Central Bank of Austria exceptionally fast, agile and robust disaster recovery and business continuity capabilities. And with our ALM technology, it delivers precise, real-time insight into the bank’s fiber plant so that any impairments or breaks can be rapidly repaired with minimal disruption. In fact, our ALM has already repaid the bank’s investment by identifying an issue at the service provider end and preventing outages from occurring,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “For a major national bank leasing dark fiber, secure connectivity is of paramount importance. With the low-latency, physical-layer encryption of our FSP 3000 ConnectGuard™, customers throughout Austria can now be sure of a frictionless experience and complete peace of mind when accessing their financial data.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005079/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
